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SUMMARY 
 
Background 
Comorbid major depression has been associated with worse survival in patients with cancer. 
However, we do not know if treating depression improves survival. In the SMaRT Oncology-
2 (good prognosis cancers) and SMaRT Oncology-3 (lung cancer, a poor prognosis cancer) 
trials, we found that a depression treatment programme, Depression Care for People with 
Cancer (DCPC), was highly effective in reducing comorbid major depression. In this analysis, 
we aimed to determine whether DCPC also had an effect on survival. 
Methods  
We obtained long-term data on deaths (all causes) in the 642 SMaRT Oncology-2 and 3 trial 
participants, censored at July 31, 2015, and analysed survival as a trial outcome. We 
estimated unadjusted hazard ratios (HRs) for each trial using Cox regression, and pooled the 
log HRs in a fixed-effects meta-analysis. 
Outcomes 
We followed up SMaRT Oncology-2 and SMaRT Oncology-3 participants for a median of one 
and five years respectively. 135/500 (27%) SMaRT Oncology-2 participants and 114/142 
(80%) SMaRT Oncology-3 participants died within this period. We found no statistically 
significant effect of DCPC on survival in the total follow-up period for either trial (SMaRT 
Oncology-2 HR 1·016, 95% CI 0·72 to 1·42, p=0·93; SMaRT Oncology-3 HR 0·82, 95% CI 0·56 
to 1·18, pooled HR 0·92, 95% CI 0·72 to 1·18, p=0·28). 
Interpretation  
DCPC is highly effective in improving depression and quality of life in depressed cancer 
patients, but does not have a statistically significant effect on survival. 
Funding 
NIHR CLAHRC Oxford, Cancer Research UK and the Chief Scientist Office of the Scottish 
Government 
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INTRODUCTION  
 
There has been longstanding controversy about whether psychiatric and psychological 
treatments improve the survival of cancer patients. Two influential trials, published more 
than 20 years ago suggested that they did.1,2  However, recent systematic reviews of this 
topic have been inconclusive, finding small effects only in subgroups of patients or at 
specific times after cancer diagnosis.3,4 Major shortcomings in the trials conducted to date 
include a lack of specific targets for the psychiatric treatments and a corresponding 
heterogeneity in the psychiatric diagnoses of trial participants. There is therefore 
considerable uncertainty about the effect of psychiatric interventions on survival and a 
corresponding need to evaluate the effect of a clearly targeted psychiatric treatment in 
cancer patients who share a specific psychiatric diagnosis. 
 
Major depression comorbid with cancer is a suitable specific psychiatric diagnosis to target. 
That is because it affects approximately 10% of cancer patients and has been round in 
multiple studies to be associated with worse survival.5-8 However, despite the association 
with worse survival, we are not aware of any trials that have aimed to find out if giving 
treatment for depression (pharmacological, psychological or both) to depressed patients 
with cancer improves their survival? 
 
In this paper, we aim to determine the effect of a multi-component depression treatment 
programme called Depression Care for People with Cancer (DCPC) on the survival of patients 
with cancer.9 Between 2008 and 2011, we conducted two randomised controlled trials 
(Symptom Management Research Trials; SMaRT Oncology-2 and SMaRT Oncology-3) 
comparing DCPC with usual care in patients with good prognosis and poor prognosis 
cancers, all of whom had comorbid major depression, and found that DCPC was much more 
effective than usual care in improving depression.10,11 DCPC also improved patients’ 
symptoms, functioning and quality of life. We aimed to find out if DCPC also improved 
participant survival.  In order to do we obtained long-term data on deaths (from all causes) 
of SMaRT Oncology-2 and 3 trial participants, and analysed survival as a trial outcome.  
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METHODS 
 
The trials: SMaRT Oncology-2 and 3 
The published protocols and trial reports for SMaRT Oncology-2 and 3 describe the trial 
methods, including the trial treatments in detail.10-13 In brief, these were both two-arm 
parallel group randomised controlled trials which compared DCPC with usual care in 
patients with cancer and comorbid major depression.  
 
DCPC is a manualised, multicomponent (with both pharmacological and psychological 
components), collaborative care treatment that is delivered systematically by a team of 
cancer nurses and psychiatrists in collaboration with oncologists and primary care 
physicians.9 DCPC was adapted in SMaRT Oncology-3 to meet the needs of patients with a 
lung cancer, a poor prognosis cancer (as Depression Care for People with Lung Cancer, 
DCPLC to achieve a rapid treatment response and to enable patients to continue treatment 
despite physical deterioration.11  Usual care was provided by the participants’ own primary 
care physician and oncology team in both trials. We registered the trials with Current 
Controlled Trials, numbers ISRCTN40568538 and ISRCTN75905964. 
 
We recruited 642 participants to these two trials from three cancer centres in Scotland, UK 
and their associated clinics.  We recruited five hundred patients with good prognosis 
cancers (predicted survival ≥12 months estimated by their cancer specialist) and comorbid 
major depression to SMaRT Oncology-2 between 12th May 2008 and 13th May 2011. We 
recruited one hundred and forty-two patients with lung cancer (predicted survival ≥3 
months) and comorbid major depression to SMaRT Oncology-3 between 5th January 2009 
and 9th September 2011. In both trials participants were randomly allocated (1:1) to either 
DCPC or usual care. 
 
This further analysis of the trial data to include survival data was approved by the Scotland A 
Research Ethics Committee (08/MRE00/23; 08/MRE00/95) and the NHS Scotland Privacy 
Advisory Committee. At the time of original trial enrolment, participants gave written 
consent for us to obtain follow-up information from their medical records.  
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Procedures 
We obtained mortality data on trial participants (dates and causes of death) from the 
National Records of Scotland database on 31st July 2015. We did this by sending a minimal 
dataset (each participant’s trial number, name, date of birth, gender, Community Health 
Index (CHI) number, postcode, and date of randomisation) securely to the Information 
Services Division of NHS Scotland for records linkage.  
 
Statistical analysis  
We calculated time to death (from any cause) from the date of each participant’s trial 
enrolment (randomisation). We censored participants who: (a) had left Scotland (at their 
date of emigration); (b) were not known to have died or to have emigrated (at the latest 
date on which data were available, which was July 31, 2015). We analysed the two trials 
separately. We used log-rank tests to compare the distribution of time to death in the trial 
arms, plotted Kaplan-Meier survival estimates for the trial arms and estimated unadjusted 
hazard ratios (HRs) for each trial using Cox regression. The Cox model estimates the ratio of 
the instantaneous risks (termed hazards) of death between the two arms of a trial, assuming 
that this ratio does not change over time (proportional hazards).  We checked for violations 
of the assumption by calculating scaled Schoenfeld residuals and plotting them against 
duration of follow up. If the assumption is correct the slope of a generalized least squares 
regression line in this graph should be zero.14 Finally, we pooled the log HRs from the two 
trials using the inverse-variance method in a fixed-effects meta-analysis to report a 
combined HR. We performed all statistical analyses using Stata v14 (StataCorp, College 
Station, TX, USA). 
 
Role of the funding source 
The funder had no role in the study design; in the collection, analysis, and interpretation of 
data; in the writing of the report; or in the decision to submit the paper for publication. The 
corresponding author had full access to all the data in the study and had final responsibility 
for the decision to submit for publication. 
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RESULTS 
 
We obtained data on all trial participants. Table 1 shows their demographic and clinical 
characteristics. We also obtained follow up data on SMaRT Oncology-2 participants (until 
the time of their death or to July 31, 2015 if that was sooner) for a median of 5·1 years 
(maximum 7·1 years) and on SMaRT Oncology-3 participants for a median of 1·2 years 
(maximum 6·5 years).  
 
[Table 1 here] 
 
135/500 (27%) SMaRT Oncology-2 participants and 114/142 (80%) SMaRT Oncology-3 
participants had died during the follow up period. The majority of deaths were cancer-
related. None of the deaths had been attributed to suicide (see Table 2). 
 
[Table 2 here] 
 
In SMaRT Oncology-2 we found no statistically significant difference in survival between 
DCPC and usual care arms of the trial (p=0·93, log rank test). Inspection suggested that the 
Kaplan-Meier survival curves diverged slightly at around one year post-randomisation in 
favour of usual care, and crossed over at five years in favour of DCPC (see Figure 1); the 
Schoenfeld residual plot also suggested the HR may decrease over follow-up time (not 
shown). However, the analogous test for a non-constant hazard ratio was not statistically 
significant (p=0.066). The hazard ratio from the Cox proportional hazards model was 1·016 
with the 95% confidence interval (0·72 to 1·42), p=0·93. This finding is consistent with both 
moderately positive and negative effect of DCPC on survival. 
 
 
[Figure 1 here] 
 
In SMaRT Oncology-3 we again found no statistically significant difference in survival 
between the two arms of the trial (p=0·28, log rank test). Whilst inspection suggested a 
steeper decline in survival probability in the usual care arm between one and two years 
7 
 
post-randomisation, and a separation in the Kaplan-Meier survival curves thereafter (see 
Figure 1), the hazard ratio of 0·82 (in favour of DCPC) with a 95% CI extending from 0·56 to 
1·18 (p=0·28) again reflects substantial uncertainty in the estimate. It is also consistent with 
both a positive effect and a modest negative effect of DCPC on survival. There was no 
statistical evidence of non-proportionality in this hazard ratio (p=0·71).  
 
Combining the two trials yielded a pooled hazard ratio for survival of 0·92 (95% CI 0·72 to 
1·18, p=0·51). This confidence interval is again consistent with moderate effects of DCPC on 
survival in both directions. It is also notable that this finding was not substantially different 
in a sensitivity analysis that included only those deaths attributed to cancer.  
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DISCUSSION 
 
Main findings 
This is the first report to investigate the effect on survival of a depression treatment 
programme (DCPC) for cancer patients with a diagnosis of comorbid major depression. 
Although DCPC has been found to be highly effective in improving depression,10,11 we found 
no statistically significant evidence that it also prolongs survival.  
 
Strengths and limitations 
This finding must be considered in the context of the strengths and limitations of the study. 
The strengths include the comparison of randomised groups, recruitment into the trials by 
systematic screening, a large observed effect of treatment on depression and high degree of 
completeness of follow up data. The study also had limitations: First, whilst the size of the 
trials analysed was sufficient to address the primary research question, it offered only 
limited power to detect a small but potentially clinically relevant effect on survival. We 
observed 135 deaths in SMaRT-2 and 114 deaths in SMaRT-3 at follow-up. This number of 
deaths provided 80% statistical power to detect a pooled HR of 0·70 at 5% statistical 
significance; a large but plausible effect. It is also worth noting that the detection of a 
smaller effect on survival would require very large numbers. For example, to have 80% 
statistical power to detect a more modest HR of 0·80, a new trial with a similar death rate at 
follow up, would need to recruit more than 1,500 patients. Second, although we were able 
to obtain long-term mortality data, we were not able to follow all trial participants to their 
date of death. Whilst this limitation makes us potentially unable to detect longer-term 
effect of depression treatment on survival, it seems unlikely that any long-term effect would 
be greater than that observed sooner after treatment for depression was given. Third, as 
SMaRT Oncology-2 and 3 only included participants who had an estimated prognosis of at 
least 12 months and at least three months respectively, our ability to detect an effect in 
patients with a very poor cancer prognosis was limited. Fourth, the trials (in particular 
SMaRT Oncology-2) included participants with heterogeneous cancer diagnoses who had 
various cancer treatments; the limited power of our analysis did not allow us to explore 
whether the effect of DCPC on survival was different for patients with different cancer types 
receiving differing cancer treatments. A final limitation is that our analysis compared 
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survival between trial arms; that is between participants randomly allocated to receive 
either DCPC or usual care, following the intention to treat principle. This design is a notably 
robust method for comparing the effect of DCPC with usual care. However, it does not 
address the related, but different question, of whether getting better from depression is 
associated with increased survival. This requires a different type of analysis of the data that 
is not based on the randomised comparison of treatments. We will report on this analysis 
elsewhere. 
 
Previous studies 
We are not aware of any previously published trials that have specifically addressed 
whether delivering depression treatment to cancer patients with comorbid major 
depression improves their survival. Of some relevance is a secondary analysis of a trial in 
which early palliative care for patients with lung cancer was found to improve survival, did 
not find that the survival effect was mediated by improving depression.15,16   
 
An association of comorbid major depression with worse survival has also been found in 
patients suffering from medical conditions other than cancer, most notably heart disease.17-
21   It is therefore of interest that trials of depression treatment in patients with heart 
disease and comorbid depression have also failed to find good evidence of improved 
survival.22-25   
 
Conclusion 
In conclusion, major depression is a common and important problem in patients with 
cancer. It is associated with both reduced quality of life and worse survival. In the SMaRT 
Oncology 2 and 3 trials of depression treatment, we observed a strong effect on depression 
and quality of life, but no convincing evidence of an effect on survival.  Despite the lack of 
effect on length of life, the beneficial effect of treatment of depression on quality of life 
provides sufficient reason to make this an important part of cancer care. 
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RESEARCH IN CONTEXT 
 
Evidence before this study 
Recent systematic reviews have suggested that psychiatric interventions might improve 
survival in some cancer patients. Studies have also found that comorbid depression in 
particular predicts worse survival. We were therefore interested in the determining the 
effect on survival of the treatment of comorbid major depression in cancer patients. We 
searched PubMed from 01/01/1900 to 01/01/2018 using the search terms cancer [Title] 
AND depress*[Title] AND surviv* [Title] AND trial* and found no papers reporting survival 
outcomes from randomised clinical trials of interventions for comorbid major depression in 
cancer patients.  
 
Added value of this study 
We compared the survival outcome of people with cancer and comorbid major depression 
given depression treatment, with that of those receiving only usual care in the SMaRT 
Oncology-2 and 3 trials. Whilst the treatment was highly effective in improving depression, 
we did not find statistically significant evidence that it also improved survival. 
 
Implications of all the available evidence 
There is no convincing evidence from clinical trials that treating comorbid depression in 
cancer patients has a substantial effect on their survival.  This finding is consistent with 
findings in patients with cardiac disease. Much larger trials with long duration of follow up 
would be required to find out if there are modest but clinically significant effects on survival. 
Nonetheless, the evidence for a beneficial effect on quality of life already indicates the 
treatment of depression in people with cancer.
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Table 1: Characteristics of SMaRT Oncology-2 and SMaRT Oncology-3 trial participants 
 
SMaRT Oncology-2 SMaRT Oncology-3 
 
 DCPC (n=253) Usual care 
(n=247) 
DCPLC (n=68) Usual care 
(n=74) 
Age at trial enrolment (years) 56·6 (10·0) 56·1 (10·2) 63·6 (8·8) 63·9 (8·7) 
Sex 
  Women 
  Men 
 
227 (90%) 
  26 (10%) 
 
222 (90%) 
  25 (10%) 
 
  44 (65%) 
  24 (35%) 
 
  48 (65%) 
  26 (35%) 
Primary cancer     
  Breast 140 (55%) 131 (53%) - - 
  Gynaecological   57 (23%)   64 (26%) - - 
  Genito-urinary   13 (5%)   14 (6%) - - 
  Other   43 (17%)   38 (15%) - - 
  Non-small cell lung cancer - -   43 (63%)   50 (68%) 
  Small cell lung cancer - -   16 (24%)   14 (19%) 
  Other lung - -     9 (13%)   10 (14%) 
Trial primary outcome     
Depression treatment response1 143 (62%)   40 (17%) - - 
Average depression severity2 - - 1·24 (0·64) 1·61 (0·58) 
Follow up time in years (median, 
IQR) 
  5·0 (4·2, 5·8)   5·1 (4·3, 5·8)   1·3 (0·5, 4·2)   1·0 (0·6, 3·0) 
Deaths   68 (27%)   67 (27%)   52 (76%)   62 (84%) 
Emigrations     0 (0%)     1 (0%)     0 (0%)     0 (0%) 
Death rate per 100 person years   6·0   5·9   33·5   44·8 
Data are mean (SD) or n (%) unless otherwise indicated.  1 50% reduction on Symptom Check List-20 
Depression subscale at 24 weeks. 2 Average depression severity (using Symptom Check List-20 Depression 
subscale) throughout the period of the participant’s trial participation up to a maximum of 32 weeks.  
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Table 2: Primary causes of death in SMaRT Oncology-2 and SMaRT Oncology-3 trial 
participants 
 
Primary cause of death SMaRT Oncology-2 participant 
deaths 
SMaRT Oncology-3 participant 
deaths 
 
 
DCPC  
(n=68) 
Usual care 
(n=67) 
DCPC  
(n=52) 
 
Usual care 
(n=62) 
Cancer 55 (81) 63 (94) 43 (83) 55 (89) 
  Breast  19 (28) 27 (40) 0 0 
  Gynaecological  20 (29) 15 (22) 0 0 
  Genitourinary  4 (6) 6 (9) 0 0 
  Lung  0 3 (4) 43 (83) 51 (82) 
  Other1 12 (18) 12 (18) 0 4 (6) 
Cardiovascular disease2 7 (10) 2 (3) 4 (8) 2 (3) 
Respiratory disease 3 (4) 1 (1) 4 (8) 1 (2) 
Other3 3 (4) 1 (1) 1 (1) 4 (6) 
     
 
Data are n(%). 1 Haematological, upper gastrointestinal, colorectal, primary peritoneal, unspecified intestinal 
and cancer of multiple primary sites. 2Myocardial infarction, chronic ischaemic heart disease, cerebrovascular 
disease, cardiac failure. 3Obstructed inguinal hernia, sarcoidosis, acute pancreatitis, gastrointestinal 
haemorrhage, liver disease, sepsis. 
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Figure 1. 
 
 
